MONDAY, Dec. 15, 2025 (HealthDay News) — Doing nothing at all to manage a common fetal heart defect might improve the ...

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies. Findings from the ...

DENVER, April 22, 2022 – A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm ...

Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Babies born prematurely can have a number of complications at birth, simply because they are brought into the world before ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

After birth, the pulmonary arterioles dilate and the right heart pressures drop. The left heart pressures increase as the low resistance placenta is replaced by the high-resistance systemic ...

In extremely preterm infants with a protocol-defined patent ductus arteriosus, death or bronchopulmonary dysplasia did not differ between the expectant management group and the active treatment group.

Expectant management is increasingly being used for patent ductus arteriosus in infants, but evidence to support this approach is limited. New research findings are summarized in a short video.